Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist DOI
María José Temido, Sailish Honap,

Anne Claire Bursztejn

и другие.

The American Journal of Gastroenterology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 9, 2024

Drug-induced acne is a common side effect to wide array of pharmacological therapies and characterized by monomorphic, papulopustular eruption typically affecting the face, scalp, upper thorax. Corticosteroids Janus kinase inhibitors (JAKi) are commonly used for treatment inflammatory bowel disease (IBD) known aggravate prior tendency or trigger development new acneiform eruptions. Recent attention on managing drug-induced has been driven increasing use JAKi, an expanding therapeutic class in IBD several other immune-mediated diseases. Both randomized controlled trials real-world studies have identified as one most treatment-emergent adverse events JAKi. Left untreated, this skin reaction can significantly affect patient self-esteem quality life leading poor adherence suboptimal control. This review examines characteristics treatments, provides practical guide gastroenterologists manage mild-to-moderate occurrences, highlights when seek specialist dermatology advice. Such approaches enable early often distressing event optimize management preventing premature discontinuation dose reduction efficacious drugs.

Язык: Английский

New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review DOI Creative Commons

M.A. Bianco,

F D’Oria,

Costanza Falcidia

и другие.

Medicina, Год журнала: 2025, Номер 61(4), С. 631 - 631

Опубликована: Март 29, 2025

Prurigo nodularis (PN) is a chronic dermatological condition characterized by intensely pruritic nodules resulting from repeated scratching. Its pathogenesis involves neuroimmune dysregulation, inflammatory cytokines, and neural proliferation. Conventional treatments often provide limited relief, necessitating novel therapeutic approaches. This narrative review explores emerging biologics small molecules for PN treatment, assessing their mechanisms, efficacy, safety. A comprehensive literature search was conducted using PubMed, Google Scholar, Web of Science relevant studies up to February 2025. Additionally, ongoing clinical trials were identified through ClinicalTrials.gov. The terms included “prurigo nodularis”, “biologic treatments”, “monoclonal antibodies”, “small molecules”, “JAK inhibitors”. Among new treatment options, dupilumab, an IL-4 receptor antagonist, nemolizumab, IL-31 inhibitor, demonstrated significant efficacy in reducing pruritus lesion severity patients. Other promising monoclonal antibodies include vixarelimab (OSMRβ inhibitor) barzolvolimab (KIT inhibitor). Small such as JAK inhibitors (upadacitinib, povorcitinib) also show potential modulating pathways. Clinical highlight safety, long-term benefits. Emerging represent transformative approach management, offering targeted therapies that address underlying immunological neurological mechanisms. Ongoing research are crucial optimizing strategies improving patient outcomes.

Язык: Английский

Процитировано

0
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study DOI Open Access
Luciano Ibba,

Costanza Falcidia,

S. Di Giulio

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(9), С. 2953 - 2953

Опубликована: Апрель 24, 2025

Background: Atopic dermatitis (AD) is a chronic pruritic inflammatory disease affecting children and adults. Upadacitinib abrocitinib are selective Janus kinase 1 inhibitors approved for the treatment of moderate-to-severe AD. Although their efficacy safety described in phase 3 clinical trials, real-world data limited. Objectives: We aimed to evaluate effectiveness upadacitinib real-life adult population with AD throughout an extended observation period. Methods: This retrospective observational study was conducted by analyzing from electronic records IRCCS Humanitas Research Hospital January 2023 December 2024. Patients were administered either (15 or 30 mg) (100 200 mg). Effectiveness evaluated using clinician-reported scores (Investigator Global Assessment [IGA] Eczema Area Severity Index [EASI]) patient-reported outcomes (peak pruritus numerical rating scale [PP-NRS]) at weeks 8, 16, 32 52. Statistical significance set probability value (p-value) < 0.05. Adverse events also collected. Results: In total, 129 patients included study, 84 them reached 52 weeks. At week 52, EASI 75, 90, 100 responses 88.9%, 70.8%, 54.2% upadacitinib, 100%, 91.7%, 75% abrocitinib. An IGA score equal 0 achieved 84.7% treated 100% those receiving A four-point reduction baseline PP-NRS reported 86.1% 83.3% after one year follow-up. Conclusions: Our showed comparable even higher terms compared phase-3 no new concerns, supporting

Язык: Английский

Процитировано

0
The Transition of Blood Biomarkers During 96-Week Treatment with Upadacitinib for Atopic Dermatitis: A Real-World Analysis Stratified by Age DOI
Teppei Hagino, Hidehisa Saeki,

Eita Fujimoto

и другие.

Dermatitis, Год журнала: 2025, Номер unknown

Опубликована: Апрель 29, 2025

Background: The transition of laboratory indexes is unknown for long-term (2-year) upadacitinib treatment in atopic dermatitis (AD). Objective: To assess the 96-week real-world effects on immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), total eosinophil count (TEC) Japanese patients with AD, stratified by age groups (<18, 18-64, ≥65 years). Methods: In this prospective, single-center study, received 15 mg or 30 plus topical corticosteroids from August 2021 to November 2024. Laboratory (IgE, TARC, LDH, TEC) clinical (eczema area severity index, peak pruritus-numerical rating scale) were measured at weeks 0, 4, 12, 24, 36, 48, 60, 72, 84, 96. Results: Upadacitinib generated a sustained reduction until week 96 all groups. TEC decreased 4 12 remained below baseline Patients aged years maintained lowest among three Conclusion: provided across parallel reduced AD. may act as potential biomarker reflecting responsiveness upadacitinib.

Язык: Английский

Процитировано

0
Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry DOI Creative Commons
Barbara Kind, Luise Heinrich, Thomas Werfel

и другие.

Acta Dermato Venereologica, Год журнала: 2025, Номер 105, С. adv42206 - adv42206

Опубликована: Май 21, 2025

Язык: Английский

Процитировано

0
Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist DOI
María José Temido, Sailish Honap,

Anne Claire Bursztejn

и другие.

The American Journal of Gastroenterology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 9, 2024

Drug-induced acne is a common side effect to wide array of pharmacological therapies and characterized by monomorphic, papulopustular eruption typically affecting the face, scalp, upper thorax. Corticosteroids Janus kinase inhibitors (JAKi) are commonly used for treatment inflammatory bowel disease (IBD) known aggravate prior tendency or trigger development new acneiform eruptions. Recent attention on managing drug-induced has been driven increasing use JAKi, an expanding therapeutic class in IBD several other immune-mediated diseases. Both randomized controlled trials real-world studies have identified as one most treatment-emergent adverse events JAKi. Left untreated, this skin reaction can significantly affect patient self-esteem quality life leading poor adherence suboptimal control. This review examines characteristics treatments, provides practical guide gastroenterologists manage mild-to-moderate occurrences, highlights when seek specialist dermatology advice. Such approaches enable early often distressing event optimize management preventing premature discontinuation dose reduction efficacious drugs.

Язык: Английский

Процитировано

1